Noradrenergic and dopaminergic interrelation in schizophrenia

Area of Science:

• Neuroendocrinology
• Psychiatry
• Pharmacology

Background:

• Schizophrenia is a complex psychiatric disorder.
• Growth hormone (GH) and prolactin (PRL) are pituitary hormones.
• Dysregulation of neuroendocrine pathways may be implicated in schizophrenia.

Purpose of the Study:

• To investigate GH and PRL responses to clonidine and apomorphine in schizophrenic patients.
• To compare hormonal responses between patients and healthy controls.
• To explore correlations between hormonal responses and clinical symptoms of schizophrenia.

Main Methods:

• 20 drug-free schizophrenic patients (subchronic and chronic) and 9 controls participated.
• Acute administration of clonidine (150 µg) and apomorphine (0.5 mg).
• Parallel measurement of GH and PRL levels before and after drug administration.

Main Results:

• No significant differences in basal GH/PRL or mean responses between groups.
• Blunted GH response to clonidine in 8 patients and apomorphine in 7 patients.
• Blunted GH response to apomorphine correlated with illness chronicity.
• Exaggerated GH response to clonidine in paranoid patients.
• Correlations found between negative symptoms and GH/PRL responses, and positive symptoms and PRL responses.

Conclusions:

• While mean hormonal responses to clonidine and apomorphine do not differ between schizophrenic patients and controls, individual variations exist.
• Blunted GH responses and their correlation with chronicity suggest neuroendocrine alterations in schizophrenia.
• Specific symptom clusters in schizophrenia are associated with distinct GH and PRL response patterns.